Navigation Links
Optimer Pharmaceuticals to Present at November 2012 Investor Conferences
Date:11/7/2012

JERSEY CITY, N.J., Nov. 7, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Company will present at the below listed investor conferences in November. The presentations will include an overview of the company and an update on recent business activities.

(Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

  • 2012 Credit Suisse Healthcare Conference on Wednesday, November 14 at 1:00 PM Eastern time at The Arizona Biltmore in Phoenix.
  • Jefferies 2012 Global Healthcare Conference in London on Thursday, November 15 at 6:20 AM Eastern time at the Waldorf Hilton in London, UK.

Live audio webcasts of the presentations will be accessible on the Investors page of the Company's website at www.optimerpharma.com.  Replays of the presentations will be available at the same location for 30 days following the conference.

About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a global biopharmaceutical company focused on developing and commercializing innovative hospital specialty products that have a positive impact on society.  Optimer developed DIFICID® (fidaxomicin) tablets, an FDA-approved macrolide antibacterial drug for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and older and is commercializing DIFICID in the US and Canada.  Optimer also received marketing authorization for fidaxomicin tablets in the European Union where its partner, Astellas Pharma Europe, is commercializing fidaxomicin under the trade name DIFICLIR™.  The Company is exploring marketing authorization in other parts of the world where C. difficile has emerged as a serious health problem, including Asia. Additional information can be found at http://www.optimerpharma.com.

Contacts
Optimer Pharmaceuticals, Inc.
David Walsey, Vice President, Investor Relations and Corporate Communications
(858) 964-3418

Canale Communications, Inc.
Jason I. Spark, Senior Vice President
(619) 849-6005


'/>"/>
SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Optimer Pharmaceuticals Reports Third Quarter 2012 Financial Results
2. Optimer Pharmaceuticals to Present at September 2012 Investor Conferences
3. Optimer Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Growth Conference
4. Optimer Pharmaceuticals Appoints Stephen Newman to Its Board of Directors
5. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2012 Financial Results
6. Optimer Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference
7. Optimer Pharmaceuticals and Specialised Therapeutics Australia Collaborate to Commercialize Fidaxomicin for Clostridium difficile Infection in Australia and New Zealand
8. First sales of DIFICLIRâ„¢ by Astellas Pharma Europe triggers 10 Million Euro Milestone Payment to Optimer Pharmaceuticals
9. Optimer Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
10. Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
11. Isis Pharmaceuticals To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)...  Oxis International Inc. (OTC/QB: OXIS) announced today that ... a "clinical trial triumph" after one of the first ... remission. Daniel Vallera , a research ... --> Daniel Vallera , a research ... --> An article on the University ...
(Date:2/10/2016)... , Feb. 10, 2016  LexisNexis® Risk ... technology, today announced the launch of LexisNexis ... solution that helps improve and optimize the quality ... of performance using severity-adjusted scores. By measuring provider ... critical solution to deliver better outcomes, improve the ...
(Date:2/10/2016)... AKIVA, Israel , February 10, 2016 ... a leader in the field of cartilage repair, announces ... February 5, 2016. The $15 million investment was led ... Chinese pharmaceutical manufacturer, and was joined by existing Regentis ... Holdings and both the Technion Research & Development Foundation ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... ... As part of its ongoing series of aquatic therapy related webinars, HydroWorx ... dynamic expert and thoughtful presentation to give attendees a better sense of how to ... free to attend, but registration is required. , Rehabilitation of Offensive Lineman ...
(Date:2/10/2016)... Garland, TX (PRWEB) , ... February 10, 2016 ... ... the commencement of a master charity program created to assist the local community. ... closely with community leaders and nonprofit organizations in the area. Their goal is ...
(Date:2/10/2016)... ... February 10, 2016 , ... Dr. Jessica Barron, of Barron Family Dental ... dental patients and families in the North Metro Denver area. The new dental practice ... cosmetic dentistry, and all in the most relaxing environment. , While some dental visits ...
(Date:2/10/2016)... ... February 10, 2016 , ... Gout is like no other joint pain. It ... severe, with intense swelling and redness. It is triggered by the crystallization of uric ... are the most susceptible, according to the February 2016 issue of Harvard Men's Health ...
(Date:2/10/2016)... Boston, Massachusetts (PRWEB) , ... February 10, 2016 ... ... practice models to effectively measure change in their patients. Research shows that the ... traditional methods. To help therapists overcome this challenge and learn more about the ...
Breaking Medicine News(10 mins):